Target intelligence / Profile preview

Epstein-Barr virus envelope glycoprotein GP350 (gp350)

Target
gp350
Molecular classification
Viral envelope glycoprotein, Viral protein, Receptor ligand
01

Overview

Epstein-Barr virus envelope glycoprotein GP350 (gp350) is the most abundant glycoprotein on the outer envelope of the Epstein-Barr virus (EBV) virion and is also expressed on the surface of EBV-infected cells during the lytic cycle. It plays a critical role in initiating viral infection by binding to complement receptor 2 (CR2/CD21) on host B lymphocytes, facilitating viral attachment and subsequent membrane fusion and entry. Because of its prominent surface exposure and essential role in viral entry, gp350 is a primary target for prophylactic and therapeutic interventions against EBV-associated diseases, including infectious mononucleosis, multiple sclerosis, and various malignancies such as Burkitt lymphoma, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disorders (PTLD).

Therapeutic strategies targeting gp350 include subunit and nanoparticle vaccines (e.g., gp350-ferritin nanoparticle vaccine, gp350/AS04 vaccine) and multi-antigen mRNA vaccines (e.g., mRNA-1189, mRNA-1195) designed to elicit neutralizing antibodies that block viral attachment. Additionally, monoclonal antibodies (such as S54 and 72A1) and chimeric antigen receptor T-cell (CAR-T) therapies are being developed to neutralize the virus and selectively eliminate gp350-expressing cells in patients with chronic active EBV or EBV-positive malignancies.

Other names
gp350gp350/220Membrane antigenMABLLF1Envelope glycoprotein GP350Epstein-Barr virus glycoprotein 350
02

Mechanism of action

Active immunization to induce neutralizing antibodies, passive immunization to block receptor binding, and CAR-T cell-mediated cytotoxicity against gp350-expressing cells.

03

Biological functions

Host-virus interactionViral entryCell adhesionReceptor ligand activity
04

Disease associations

InfectionInfectious mononucleosisCancerLymphomaBurkitt lymphomaNasopharyngeal carcinomaPost-transplant lymphoproliferative disorderMultiple sclerosisChronic active Epstein-Barr virus infection
05

Safety considerations

Incomplete protection / lack of sterilizing immunity (does not prevent asymptomatic infection)Cytokine release syndrome (CRS) and neurotoxicity in CAR-T therapiesMild to moderate vaccine reactogenicity (injection site pain, fatigue, headache)Potential for immune evasion or selection of escape mutants
06

Interacting drugs

gp350/AS04 vaccine

6 more in the full profile.

07

Biomarkers

Anti-gp350 antibody titersEBV DNA viral loadgp350 expression on peripheral blood lymphocytesEBV-encoded small RNA (EBER) status

Beyond the preview

Go deeper on Epstein-Barr virus envelope glycoprotein GP350 (gp350).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epstein-Barr virus envelope glycoprotein GP350 (gp350).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call